Login
Home
Charts
Search
Watchlist
Products

Fairchem Organics Ltd

FAIRCHEMOR·NSE
625.80-1.70%Wed, 23 Sept '26 13:33

Fairchem Organics Ltd

FAIRCHEMOR
NSE
625.80
-1.70%
|Wed, 23 Sept '26 13:33
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
788Cr
Close
Close Price
625.80
Industry
Industry
Chemicals - Organic
PE
Price To Earnings
55.28
PS
Price To Sales
1.56
Revenue
Revenue
505Cr
Rev Gr TTM
Revenue Growth TTM
0.14%
PAT Gr TTM
PAT Growth TTM
54.68%

Quarterly Results

Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
152148161165139114121131112100117176
Growth YoY
Revenue Growth YoY%
-9.744.55.72.7-8.9-23.3-24.8-20.5-19.6-11.8-3.234.4
Expenses
ExpensesCr
13512814214313010611612610796109158
Operating Profit
Operating ProfitCr
17201922984544818
OPM
OPM%
11.113.311.713.26.36.93.74.03.84.26.910.1
Other Income
Other IncomeCr
000000000-110
Interest Expense
Interest ExpenseCr
111111111112
Depreciation
DepreciationCr
223333333333
PBT
PBTCr
14171619551210514
Tax
TaxCr
444511100014
PAT
PATCr
10121214441110410
Growth YoY
PAT Growth YoY%
157.31,921.3-0.8126.3-61.0-71.5-95.0-91.5-80.8-102.8525.4755.6
NPM
NPM%
6.88.37.38.42.93.10.50.90.7-0.13.25.7
EPS
EPS
7.99.59.010.63.12.70.50.90.6-0.12.98.0
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
152148161165139114121131112100117176
Growth YoY
Revenue Growth YoY%
-9.744.55.72.7-8.9-23.3-24.8-20.5-19.6-11.8-3.234.4
Expenses
ExpensesCr
13512814214313010611612610796109158
Operating Profit
Operating ProfitCr
17201922984544818
OPM
OPM%
11.113.311.713.26.36.93.74.03.84.26.910.1
Other Income
Other IncomeCr
000000000-110
Interest Expense
Interest ExpenseCr
111111111112
Depreciation
DepreciationCr
223333333333
PBT
PBTCr
14171619551210514
Tax
TaxCr
444511100014
PAT
PATCr
10121214441110410
Growth YoY
PAT Growth YoY%
157.31,921.3-0.8126.3-61.0-71.5-95.0-91.5-80.8-102.8525.4755.6
NPM
NPM%
6.88.37.38.42.93.10.50.90.7-0.13.25.7
EPS
EPS
7.99.59.010.63.12.70.50.90.6-0.12.98.0

Profit & Loss

Standalone
Numbers
Percentage
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
306397643648621538460505
Growth
Revenue Growth%
29.462.20.8-4.1-13.4-14.60.1
Expenses
ExpensesCr
258328538576554495438470
Operating Profit
Operating ProfitCr
48691057267432234
OPM
OPM%
15.817.416.311.210.88.04.76.8
Other Income
Other IncomeCr
70011101
Interest Expense
Interest ExpenseCr
77764445
Depreciation
DepreciationCr
67789111111
PBT
PBTCr
425691595530719
Tax
TaxCr
813231514825
PAT
PATCr
354268444122614
Growth
PAT Growth%
22.459.8-35.9-6.9-45.7-74.854.7
NPM
NPM%
11.310.710.66.76.54.11.22.9
EPS
EPS
26.632.652.133.431.116.94.311.3
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
306397643648621538460505
Growth
Revenue Growth%
29.462.20.8-4.1-13.4-14.60.1
Expenses
ExpensesCr
258328538576554495438470
Operating Profit
Operating ProfitCr
48691057267432234
OPM
OPM%
15.817.416.311.210.88.04.76.8
Other Income
Other IncomeCr
70011101
Interest Expense
Interest ExpenseCr
77764445
Depreciation
DepreciationCr
67789111111
PBT
PBTCr
425691595530719
Tax
TaxCr
813231514825
PAT
PATCr
354268444122614
Growth
PAT Growth%
22.459.8-35.9-6.9-45.7-74.854.7
NPM
NPM%
11.310.710.66.76.54.11.22.9
EPS
EPS
26.632.652.133.431.116.94.311.3

Balance Sheet

Standalone
Numbers
Percentage
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
0131313131313
Reserves
ReservesCr
114156219246277289250
Current Liabilities
Current LiabilitiesCr
635167672679104
Non Current Liabilities
Non Current LiabilitiesCr
29392516182124
Total Liabilities
Total LiabilitiesCr
219259324342334402391
Current Assets
Current AssetsCr
7598137149133181172
Non Current Assets
Non Current AssetsCr
144161187194201221219
Total Assets
Total AssetsCr
219259324342334402391
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
0131313131313
Reserves
ReservesCr
114156219246277289250
Current Liabilities
Current LiabilitiesCr
635167672679104
Non Current Liabilities
Non Current LiabilitiesCr
29392516182124
Total Liabilities
Total LiabilitiesCr
219259324342334402391
Current Assets
Current AssetsCr
7598137149133181172
Non Current Assets
Non Current AssetsCr
144161187194201221219
Total Assets
Total AssetsCr
219259324342334402391

Cash Flow

Standalone
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
3140405074-1742
Investing Cash Flow
Investing Cash FlowCr
-24-23-34-14-18-26-14
Financing Cash Flow
Financing Cash FlowCr
-7-17-6-35-5742-28
Net Cash Flow
Net Cash FlowCr
0000000
Free Cash Flow
Free Cash FlowCr
11763557-4228
CFO To PAT
CFO To PAT%
89.893.259.6114.0183.9-76.4750.8
CFO To EBITDA
CFO To EBITDA%
64.557.538.668.6111.2-39.2192.4
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
3140405074-1742
Investing Cash Flow
Investing Cash FlowCr
-24-23-34-14-18-26-14
Financing Cash Flow
Financing Cash FlowCr
-7-17-6-35-5742-28
Net Cash Flow
Net Cash FlowCr
0000000
Free Cash Flow
Free Cash FlowCr
11763557-4228
CFO To PAT
CFO To PAT%
89.893.259.6114.0183.9-76.4750.8
CFO To EBITDA
CFO To EBITDA%
64.557.538.668.6111.2-39.2192.4

Ratios

Standalone
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
9751,9591,1901,5461,141565788
Price To Earnings
Price To Earnings
22.928.927.438.251.998.555.3
Price To Sales
Price To Sales
2.53.01.82.52.11.21.6
Price To Book
Price To Book
5.88.44.65.33.82.13.0
EV To EBITDA
EV To EBITDA
15.019.317.123.228.129.925.9
Profitability Ratios
Profitability Ratios
GPM
GPM%
24.025.921.416.917.716.413.213.2
OPM
OPM%
15.817.416.311.210.88.04.76.8
NPM
NPM%
11.310.710.66.76.54.11.22.9
ROCE
ROCE%
28.127.733.421.019.89.23.23.2
ROE
ROE%
30.525.229.316.814.07.32.12.1
ROA
ROA%
15.916.420.912.712.15.51.41.4
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
9751,9591,1901,5461,141565788
Price To Earnings
Price To Earnings
22.928.927.438.251.998.555.3
Price To Sales
Price To Sales
2.53.01.82.52.11.21.6
Price To Book
Price To Book
5.88.44.65.33.82.13.0
EV To EBITDA
EV To EBITDA
15.019.317.123.228.129.925.9
Profitability Ratios
Profitability Ratios
GPM
GPM%
24.025.921.416.917.716.413.213.2
OPM
OPM%
15.817.416.311.210.88.04.76.8
NPM
NPM%
11.310.710.66.76.54.11.22.9
ROCE
ROCE%
28.127.733.421.019.89.23.23.2
ROE
ROE%
30.525.229.316.814.07.32.12.1
ROA
ROA%
15.916.420.912.712.15.51.41.4
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Fairchem Organics is a specialty chemical company built on a single, unusual idea: take the low-grade waste streams that edible-oil refineries cannot use - materials with no technical specifications - and turn them into high-purity ingredients that global paint and nutrition companies depend on. The business has operated for three decades from one plant in Gujarat, originally as part of Adi Finechem, and was demerged into a standalone listed entity in 2020 under the control of Fairfax India. Everything the company does follows a recurring logic - buy waste nobody else wants, apply proprietary process know-how to upgrade it, and sell the output as an import substitute to customers who value just-in-time Indian supply over Chinese cargoes. # Business segments Two engines fed by the same raw-material stream - a specialty oleochemicals business that supplies India’s paint and coatings industry, and an intermittent nutraceuticals business that exports intermediates to global life-science majors when prices permit. ## 1. Specialty oleochemicals: the paint-industry supplier that runs on waste **The company converts acid oil and deodorizer distillate - by-products that form barely 1.5% of refined vegetable oil - into fatty acids that go into paints, inks and adhesives, and it holds a commanding domestic position by pricing just below the landed cost of Chinese imports.** - **Waste is the cost advantage** - the core raw materials, Acid Oil (\~1.25% of soft-oil refining) and Deodorizer Distillate (\~0.25% of hard-oil refining), are bought “as is where is” at the refinery gate with no quality specifications, giving the company a structural cost edge over global competitors who use virgin vegetable oils or tall oils. - **Priced to own the market** - for Dimer Acid, its largest product, the company deliberately sets its price about 1-2% below the landed cost of the Chinese equivalent plus non-cenvatable customs duty, a strategy that has locked in roughly 65% domestic market share. - **The only Indian source for several molecules** - it is the sole domestic manufacturer of Dimer Acid and of the grade of Linoleic Acid needed for premium paints, and it was the first in India - and possibly Asia - to produce Isostearic Acid at internationally acceptable quality, with only 3-4 competitors worldwide. - **Customers stay for decades** - the business is purely B2B, selling directly to names like Asian Paints, BASF, Arkema and ADM, with relationships stretching beyond 25 years; domestic sales account for 91% of revenue, and most material moves within a 500 km radius. - **One plant, Swiss-German equipment, zero-discharge** - the single facility at Sanand, Gujarat, has a raw-material throughput capacity of 120,000 tonnes a year, uses Short Path Distillation and Fractionation gear from Germany and Switzerland, and runs a Zero Liquid Discharge system that recycles all wastewater. ## 2. Intermediate nutraceuticals: an export option switched on when prices work **The same deodorizer distillate that feeds the oleochemicals stream also yields Mixed Tocopherols and Sterols - natural antioxidant precursors sold exclusively to global giants like BASF and Cargill, but only when export realisations justify the raw-material cost.** - **Natural Vitamin E precursors** - Tocopherols are concentrated by customers into Natural Vitamin E, which commands a price 3-4 times that of synthetic Vitamin E and is used in pharmaceuticals, cosmetics and pet food. - **India’s dominant producer, but intermittent** - the company is the leading Indian manufacturer of Mixed Tocopherol Concentrate, yet it ran zero volume in FY26 and only small-scale operations in FY25 and FY24 because intermediate-product export prices were unremunerative relative to what Indian raw-material suppliers charge. - **Kept warm for upgrading** - the company has deliberately maintained minimal operations in lean years to preserve the option of later moving to higher-concentration tocopherols and a separate high-purity sterol stream. # Group structure and partners **Fairchem Organics is a standalone, subsidiary-free company controlled by Fairfax India, with a clean separation from its former promoter group.** - The parent company is Fairfax Group; total promoter holding stood at 63.2% after a buyback in early 2026. - The company was created through a court-sanctioned demerger effective August 2020, which carved the oleochemicals and nutraceuticals undertaking out of Fairchem Speciality Limited (now Privi Speciality Chemicals) and listed it separately; legacy shareholders received one Fairchem Organics share for every three held in the former parent. - Fairfax’s control was cemented through a 2019 share-purchase agreement with the Privi Group sellers, followed by a mandatory open offer in December 2020 that attracted negligible tender - only 290 shares - leaving the acquirer firmly in charge. - The company has no subsidiaries, associates or joint ventures, and its board comprises one executive director - the Chairman and Managing Director - alongside five non-executive directors, four of whom are independent.

Documents — Fairchem Organics Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/ndaom859rvm8nptrgscmwbuw.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/jfvyorm2i1q65dxlqbk6khaz.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/z2se7cp1vdrceeov8o03us9y.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/vvg7cvjguat8gmb7muxeova3.pdf
  • Q1 FY2026 Earnings Call Transcript (Jun 2025, PDF): https://www.stockscans.in/document/dr84hvkl4kgroev4f6zxg39q.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/bhpzj38rwo4av5xw9iaj1gy9.pdf
  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/deyun170n441i64dv2ufp5yl.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/z23yozmz71lroliovf2t8e1z.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/lcan5d2z8jdzexmaqku5d479.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/yw3hx7iooh0qulbh19nw4su0.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/urwiznv90idd8bp6zfa3mh3y.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/sokiqvxrb5pugypebtd23nno.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/e754sehemvuinjdh4wpijqrf.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/r1leiw00vq44uthmgs1i0j28.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/d3hgomgs74tb1u30mjk03lmw.pdf
  • Q1 FY2025 Quarterly Result (Jun 2024, PDF): https://www.stockscans.in/document/homulvsgneuj2haz4zqwtqt8.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/hfrns5ytffkv8zms3sf18rdh.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/8my4cqisa48tds7y0lwgrpr4.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/37j1qb11t5p0o0tp4slfuhxx.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/z2kjt0swabjln00i7fs5un8i.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/y24w6g9ih3mpch7lnjbhooc0.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/cbqmnjyohno69922n724x6zd.pdf
  • Q3 FY2025 Investor Presentation (Dec 2024, PDF): https://www.stockscans.in/document/n1a7g6ubi0dg5q4vypomo9cp.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/48rwq0ru863svh8tsbcb4jgy.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/g3flzgqjljh0dnrlolcofb6w.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/6evxc0wjcp204ixmvzb5pmqw.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/zxnwovx6te3vbfqxntjlp3ke.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/97svkd6ucllckh65frpb64x6.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/12oahybcx9zr8vavlynv12r3.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/n5up4i8b3shfc8n0tf5jhl1a.pdf

Concall Transcript Summaries — Fairchem Organics Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3AFAIRCHEMOR/transcript-notes/202606/ndaom859rvm8nptrgscmwbuw.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3AFAIRCHEMOR/transcript-notes/202603/jfvyorm2i1q65dxlqbk6khaz.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3AFAIRCHEMOR/transcript-notes/202512/z2se7cp1vdrceeov8o03us9y.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3AFAIRCHEMOR/transcript-notes/202509/vvg7cvjguat8gmb7muxeova3.pdf
  • Q1 FY2026 Concall Transcript Summary (Jun 2025): https://www.stockscans.in/company/NSE%3AFAIRCHEMOR/transcript-notes/202506/dr84hvkl4kgroev4f6zxg39q.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3AFAIRCHEMOR/transcript-notes/202503/bhpzj38rwo4av5xw9iaj1gy9.pdf
  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/NSE%3AFAIRCHEMOR/transcript-notes/202412/deyun170n441i64dv2ufp5yl.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/NSE%3AFAIRCHEMOR/transcript-notes/202409/z23yozmz71lroliovf2t8e1z.pdf